SEO URLwww.firestrike.ai/deals/astria-therapeutics-inc-biocryst-acquisition-2026
acquisitionAnnounced · Feb 23, 2026BiopharmaceuticalSource · CredibleArticle · Factual
BioCryst acquires Astria Therapeutics, Inc.
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
$920M
Target
Astria Therapeutics, Inc.
Nasdaq: ATXS
Acquirer
BioCryst
Full Acquisition
Status
Pending
BioCryst agreed to acquire Astria Therapeutics, Inc.. Reported deal value: $920M. Status: Pending. Sector: Biopharmaceutical. Target headquarters context: Location not specified.
This page summarizes publicly available information about the transaction as of 2026-02-23. Figures and status may change as filings and press coverage update.
Evercore ISI Sees Long - Term Growth Potential For BioCryst Pharmaceuticals , Inc. Following Astria Acquisition BioCryst Pharmaceuticals , Inc. tops our list for being one of the oversold stocks
Deal timeline
Announced
Feb 23, 2026 · finance.yahoo.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Biopharmaceutical with a reported deal value of $920M. Figures and status may change as sources update.
Sources: finance.yahoo.com · Primary article · FireStrike proprietary index